Physician profile
Paul R Deaton
NPI 1235110313
$9,739.48
in general payments reported to CMS, 2019-2025
39 companies · $2,399 in 2025
The $2,399 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $625 · 2021: $940 · 2022: $959 · 2023: $1,511 · 2024: $1,935 · 2025: $2,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,844.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,780.05 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,545.10 | 2019-2025 | Fasenra, Breztri, Tezspire |
| United Therapeutics Corporation | $932.89 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $741.44 | 2020-2025 | Opsumit, Uptravi, Opsynvi |
| Genzyme Corporation | $545.89 | 2019-2025 | |
| Insmed, INC. | $517.08 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.30 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genentech USA, INC. | $410.46 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $351.61 | 2022-2025 | Dupixent |
| Harmony Biosciences LLC | $267.48 | 2021-2025 | Wakix |
| Merck Sharp & Dohme LLC | $225.95 | 2019-2025 | Zerbaxa, Recarbrio, Keytruda |
| Grifols USA, LLC | $221.66 | 2019-2025 | Prolastin-C Liquid |
| Inari Medical, INC. | $207.64 | 2019 | |
| Mylan Specialty L.P. | $196.13 | 2019-2024 | Yupelri |
| Amgen INC. | $129.30 | 2024-2025 | Tezspire |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $128.73 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $87.36 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.08 | 2021-2025 | Glassia |
| Novartis Pharmaceuticals Corporation | $80.76 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $79.71 | 2020-2022 | |
| Lilly USA, LLC | $78.37 | 2025 | Zepbound |
| La Jolla Pharmaceutical Company | $77.93 | 2020-2023 | Giapreza |
| Ani Pharmaceuticals, INC. | $65.82 | 2022-2024 | Purified Cortrophin Gel |
| Pfizer INC. | $63.58 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $63.00 | 2019-2021 | |
| Baxter Healthcare | $60.99 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $56.73 | 2021-2025 | |
| Mallinckrodt Enterprises LLC | $48.98 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $33.53 | 2020 | |
| Vapotherm INC | $33.18 | 2020-2022 | |
| Viatris Specialty LLC | $30.94 | 2025 | Yupelri |
| Gilead Sciences, INC. | $26.98 | 2021 | |
| Allergan, INC. | $25.36 | 2019-2020 | |
| Csl Behring | $21.89 | 2021 | |
| Caris Mpi, INC. | $18.85 | 2025 | Mi Cancer Seek |
| Philips North America LLC | $18.11 | 2021 | |
| Inogen, INC. | $14.61 | 2022 | |
| Advanced Respiratory, INC | $12.01 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Deaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.